Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: A randomized, double‐blind, split‐face comparative study

Suwanchatchai, Warisorn; Tanglertsampan, Chuchai; Pengsalae, Nopparat; Makornwattana, Manchima

doi:10.1111/j.1346-8138.2012.01579.x

Cited by 21 publications

(26 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To the authors' knowledge, this is the first randomized, double-blind, vehicle-controlled study of the efficacy and safety of bimatoprost 0.03% ophthalmic solution to enhance eyebrow appearance. The results discussed below are consistent with those of earlier studies 5,8,9 in which bimatoprost was applied for only 3 or 4 months, as opposed to 9 months in the present study.…”

Section: Discussionsupporting

confidence: 93%

“…Skin pigmentation was not observed in either patient. Suwanchatchai and colleagues compared eyebrow enhancement of bimatoprost with that of minoxidil and did not report skin pigmentation in any of the 27 patients who completed the study. Of the seven named references, three described the use of bimatoprost for eyebrow enhancement, and two of those did not report skin pigmentation.…”

Section: Discussionmentioning

confidence: 99%

“…Suwanchatchai and colleagues compared eyebrow enhancement of bimatoprost with that of minoxidil and did not report skin pigmentation in any of the 27 patients who completed the study. Of the seven named references, three described the use of bimatoprost for eyebrow enhancement, and two of those did not report skin pigmentation. In contrast, the remaining references reported skin pigmentation when bimatoprost was used for ophthalmic purposes or to enhance eyelashes .…”

Section: Discussionmentioning

confidence: 99%

“…The skin was slightly pigmented, and the eyelash had been treated as well. That same year, Suwanchatchai and colleagues showed that bimatoprost enhances eyebrows as effectively as minoxidil. These encouraging results suggest that bimatoprost ophthalmic solution enhances the appearance of eyebrows.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Treatment of Eyebrow Hypotrichosis Using Bimatoprost: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study

Beer¹,

Julius²,

Dunn³

et al. 2013

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Eyebrow Hypotrichosis Using Bimatoprost: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study

Beer¹,

Julius²,

Dunn³

et al. 2013

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…In another study of 27 subjects with eyebrow hypotrichosis, bimatoprost increased eyebrow growth from baseline, as measured by hair diameter. 21 Contact dermatitis occurred in 3 (11.1%) of the 27 subjects.…”

Section: Discussionmentioning

confidence: 96%

Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis

Carruthers

Beer

Carruthers

et al. 2016

Dermatologic Surgery

View full text Add to dashboard Cite

BACKGROUNDEyebrow loss may have substantial negative functional and social consequences.OBJECTIVEEvaluate the safety and efficacy of bimatoprost 0.03% in subjects with eyebrow hypotrichosis.METHODSThis multicenter, double-masked study randomized adult females or males with eyebrow hypotrichosis to receive bimatoprost 0.03% twice (BID) or once daily (QD) or vehicle BID for 7 months. Primary endpoint was overall eyebrow fullness at Month 7. Secondary endpoints included eyebrow fullness (mm2), darkness (intensity units), and subject satisfaction with treatment. Safety was also assessed.RESULTSAt Month 7, the proportion of subjects with improvement was significantly higher in bimatoprost groups versus vehicle (both, p < .001). Improvements occurred in both bimatoprost groups versus vehicle after Month 1 and continued through follow-up; eyebrow fullness and darkness improved as early as Months 2 and 1, respectively (both, p < .001). Greater satisfaction was reported with bimatoprost versus vehicle at Month 2 and all subsequent time points. Overall, 38.1%, 42.4%, and 35.5% of subjects in the bimatoprost BID, QD, and vehicle groups, respectively, experienced ≥1 treatment-emergent adverse event (TEAE). Most frequent TEAEs were similar across groups. No skin or iris hyperpigmentation or conjunctival hyperemia occurred.CONCLUSIONBimatoprost 0.03% BID and QD is safe, well tolerated, and effective for eyebrow hypotrichosis.

show abstract

Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors

Bhoyrul

Asfour

Lutz³

et al. 2021

JAMA Dermatol

View full text Add to dashboard Cite

IMPORTANCE Alopecia induced by classic chemotherapy affects up to 65% of patients and is usually reversible. However, there are increasing reports of persistent chemotherapy-induced alopecia (pCIA), especially for patients treated with taxane-containing chemotherapy regimens.OBJECTIVE To analyze the clinicopathologic characteristics and response to treatment of patients with pCIA after chemotherapy for breast cancer.DESIGN, SETTING, AND PARTICIPANTS In this case series, a retrospective evaluation was performed of patients with a diagnosis of pCIA after chemotherapy for breast cancer in 4 specialist hair clinics from November 1, 2011, to February 29, 2020.MAIN OUTCOMES AND MEASURES Clinical, trichoscopic, and histopathologic characteristics and treatment outcomes were analyzed. For patients who presented with diffuse alopecia or diffuse rarefaction of hair over the midfrontal scalp with widening of the central part line and preservation of the frontal hairline, the Sinclair scale (grades 1-5, where 1 indicates normal hair density and 5 indicates the most severe stage of hair loss, with little or no hair in the centroparietal region) was used to assess severity. RESULTSOne hundred patients (99 women [99%]; mean age at presentation, 54.0 years [range, 29.0-74.1 years]) were included. Most patients had diffuse nonscarring alopecia (n = 39), female pattern hair loss (n = 55), or male pattern hair loss (n = 6). Six patients developed cicatricial alopecia. Taxane-containing regimens were used for most patients (92 [92%]) and were associated with more severe alopecia than regimens that did not contain taxanes (median Sinclair grade, 4 [IQR, 3-5] vs 2 [IQR, 2-2.5]; P < .001). A total of 76 of 86 patients (88%) had trichoscopic signs indistinguishable from those of androgenetic alopecia. Of 18 patients who had biopsies, 14 had androgenetic alopecia-like features, 2 had cicatricial alopecia, and 2 had features of both. Both topical and oral minoxidil, sometimes combined with antiandrogen therapy, were associated with an improvement in hair density (median Sinclair grade, 4 [IQR, 3-5] before treatment vs 3 [IQR, 2-4] after treatment; P < .001).CONCLUSIONS AND RELEVANCE This case series outlines previously unreported features of pCIA in patients with breast cancer, including a trichoscopic description. Cosmetically significant regrowth was achieved for a significant proportion of patients with topical or systemic treatments, suggesting that pCIA may be at least partly reversible.

show abstract

Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: A randomized, double‐blind, split‐face comparative study

Cited by 21 publications

References 5 publications

Treatment of Eyebrow Hypotrichosis Using Bimatoprost: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study

Treatment of Eyebrow Hypotrichosis Using Bimatoprost: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study

Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis

Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors

Contact Info

Product

Resources

About